Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease

Abstract

Background Patients with Crohn disease have debilitating psychological symptoms, mental fatigue, and poor quality of life. Psychological intervention may improve these symptoms. Methods We performed a randomized parallel-group physician-blinded trial of cognitive-behavioral and mindfulness-based stress reduction (COBMINDEX) on quality of life and psychological symptoms in adults with mild-moderate Crohn disease. COBMINDEX was taught by social workers in one-on-one video conferences over 3 months; quotidian home practice was mandated. Results Fifty-five COBMINDEX and 61 waitlist control patients completed the study; mean age was 33 years and 65% of participants were women. At 3 months, COBMINDEX patients had significantly reduced disease activity (per Harvey-Bradshaw Index score, C-reactive protein level, and calprotectin level), increased quality of life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ] score increased from baseline 41 to 50; P < 0.001), decreased psychological symptoms (Global Severity Index [GSI], 0.98-0.70; P < 0.001), reduced fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue, 26-33; P < 0.001), and increased mindfulness disposition (Freiburg Mindfulness Inventory, 33-38; P < 0.001). Waitlist patients had a significant but small change in Harvey-Bradshaw Index, SIBDQ, and GSI scores, without improvement in fatigue or mindfulness. There were significant correlations (0.02 > P < 0.002) in COBMINDEX patients between baseline SIBDQ, GSI, Freiburg Mindfulness Inventory, and Functional Assessment of Chronic Illness Therapy-Fatigue scores with a relative change (baseline to 3 months) of the SIBDQ score, but none among waitlist patients. Predictors of relative change of the SIBDQ score in COBMINDEX patients included the GSI score (90% quantile; coefficient 0.52; P < 0.001), somatization (90%; 0.20; P = 0.001), depression (75%; 0.16; P = 0.03), and phobic anxiety (75%; 0.31; P = 0.008). Conclusions COBMINDEX was effective in increasing patients’ quality of life and reducing psychological symptoms and fatigue. Patients with severe baseline psychological symptoms benefited the most from COBMINDEX.

Teaching and Practicing Cognitive-Behavioral and Mindfulness Skills in a Web-Based Platform among Older Adults through the COVID-19 Pandemic: A Pilot Randomized Controlled Trial

“…The two main components of the intervention were (a) guided group discussions, and (b) learning and practicing CBT techniques and skills (e.g., breathing, guided imagery of a 'safe place', constructing positive self-talk, mindfulness meditations, and more) aimed at identifying non-adaptive cognitive schemes and developing capacities to promote better coping. The collection of therapeutic techniques in our intervention protocol is based on recent evidence indicating that combined mindfulness-CBT programs were found effective in assisting people to cope with a variety of health conditions such as anxiety [37], insomnia [38], and Crohn's disease [39].…”

The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens

“…Therefore, the authors concluded that COBMINDEX has improved patients quality of life and reduced psychiatric symptoms and fatigue. Actually, patients with severe early psychological symptoms most benefited from COBMINDEX [ 198 ].…”

Understanding and managing psychological disorders in patients with inflammatory bowel disease: a practical guide

“…Mindfulness-based therapies have a modest effect in IBD on QOL, stress and depression but have no effect on anxiety 54 55. CBT can be combined with mindfulness and in one recent randomised controlled trial (RCT) was shown to reduce psychological symptoms and fatigue in patients with mild-to-moderate Crohn’s disease 56…”